D. E. Shaw & Co. Inc. Invests $5.15 Million in Disc Medicine, Inc. (NASDAQ:IRON)

D. E. Shaw & Co. Inc. acquired a new stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 81,190 shares of the company's stock, valued at approximately $5,147,000. D. E. Shaw & Co. Inc. owned 0.27% of Disc Medicine at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. FMR LLC increased its stake in Disc Medicine by 358.7% in the 4th quarter. FMR LLC now owns 1,866,248 shares of the company's stock valued at $118,320,000 after buying an additional 1,459,434 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Disc Medicine by 23.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company's stock worth $88,421,000 after buying an additional 262,690 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Disc Medicine during the 4th quarter worth $5,579,000. Renaissance Technologies LLC acquired a new position in shares of Disc Medicine during the 4th quarter worth approximately $5,479,000. Finally, Dimensional Fund Advisors LP raised its stake in Disc Medicine by 160.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 139,720 shares of the company's stock valued at $8,856,000 after purchasing an additional 86,154 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

Disc Medicine Stock Up 0.8%

Shares of IRON stock traded up $0.39 during mid-day trading on Tuesday, reaching $50.08. The stock had a trading volume of 310,725 shares, compared to its average volume of 349,692. The firm's 50 day simple moving average is $46.01 and its 200 day simple moving average is $55.04. The firm has a market cap of $1.73 billion, a PE ratio of -12.58 and a beta of 0.77. Disc Medicine, Inc. has a one year low of $30.65 and a one year high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). Sell-side analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Mona Ashiya sold 83,182 shares of Disc Medicine stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $54.45, for a total transaction of $4,529,259.90. Following the completion of the transaction, the director now directly owns 194,209 shares of the company's stock, valued at $10,574,680.05. This trade represents a 29.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William Jacob Savage sold 2,100 shares of Disc Medicine stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $50.17, for a total transaction of $105,357.00. Following the transaction, the insider now directly owns 66,398 shares of the company's stock, valued at $3,331,187.66. This represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 342,833 shares of company stock worth $18,602,418 in the last 90 days. 4.24% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. TD Cowen began coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They set a "buy" rating for the company. Morgan Stanley restated an "overweight" rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Friday, March 7th. BMO Capital Markets boosted their target price on Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a report on Monday, May 12th. Wedbush reiterated an "outperform" rating and issued a $90.00 price target (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, Cantor Fitzgerald lifted their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $98.80.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.